Boston Scientific (NYSE:BSX) reported fourth-quarter results that topped analyst estimates, driven by a double-digit surge in its cardiovascular division and a string of regulatory wins that are reshaping its competitive landscape.
The Marlborough, Massachusetts-based manufacturer said Wednesday that fourth-quarter net sales rose 15.9% to $5.286 billion.
On an organic basis—which excludes the impact of currency and recent deal-making—sales grew 12.7%.
The performance was anchored by the Cardiovascular segment, which saw a reported revenue increase of 18.2%, led by the continued global rollout of the FARAPULSE pulsed field ablation (PFA) system.
Adjusted earnings for the quarter were 80 cents per share, surpassing the company’s own guidance range of 77 to 79 cents.
For the full year 2025, Boston Scientific delivered $20.074 billion in net sales, marking a nearly 20% increase from the prior year and underscoring its status as a top performer in the MedTech sector.
"2025 was another exceptional year where our team delivered differentiated innovation that enabled us to exceed our goals," CEO Mike Mahoney said in the statement.
The company is moving aggressively to maintain this momentum through a spree of strategic acquisitions.
In recent months, Boston Scientific has announced definitive agreements to acquire Penumbra for approximately $11 billion and Valencia Technologies, while successfully closing the purchase of Nalu Medical.
These moves are designed to bolster the firm’s portfolio in neurostimulation and mechanical thrombectomy.
Regulatory momentum also reached a fever pitch in the quarter.
The company secured FDA and CE mark approvals for its FARAPOINT PFA catheter and launched the SEISMIQ intravascular lithotripsy (IVL) system.
It also received clearance for the TheraSphere 360, a move expected to drive growth in its interventional oncology business.
Looking ahead to 2026, Boston Scientific issued guidance that reflects sustained confidence.
The company projects reported net sales growth of 10.5% to 11.5% and adjusted EPS in the range of $3.43 to $3.49.